A tragic paradox, Gilead updates, and lots of Pfizer news

Adam Feuerstein/STAT

Matthew Herper covers medical innovation — both its promise and its perils.

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

Angus Chen covers all issues broadly related to cancer including drugs, policy, science, and equity. He joined STAT in 2021 after covering health and science at NPR and NPR affiliate stations. His work has been recognized by national Edward R. Murrow awards, the June L. Biedler prize for cancer journalism, and more. You can reach Angus on Signal at angus.08.

This is the web version of STAT’s special newsletter from the annual meeting of the American Society of Oncology. For more updates on the latest in cancer news, sign up for our Cancer Briefing newsletter here.

ASCO is usually sweltering, but it’s surprisingly chilly today. We’re back with a roundup of tragic paradoxes, a race for new breast cancer drugs, and all that jazz.

First, though, we want to thank everyone who turned out for our STAT@ASCO event last night. It was a packed house, and a great crowd. A reminder: Our virtual STAT Recap event about the conference will be Wednesday, and it is not too late to sign up.

STAT+ Exclusive Story

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Senior Writer, Medicine, Editorial Director of Events
Matthew Herper covers medical innovation — both its promise and its perils.
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.
Angus Chen covers all issues broadly related to cancer including drugs, policy, science, and equity. He joined STAT in 2021 after covering health and science at NPR and NPR affiliate stations. His work has been recognized by national Edward R. Murrow awards, the June L. Biedler prize for cancer journalism, and more. You can reach Angus on Signal at angus.08.